News and insights

Subscribe to our newsletter
Cancer drug resistance

IBM Watson Health (NYSE: IBM) and the of MIT and Harvard today announced a research initiative aimed at discovering the basis of cancer drug resistance. The five year, $50 million project will study thousands of drug resistant tumors and draw on Watson’s computational and machine learning methods to help researchers understand how cancers become resistant to therapies. The anonymized data will be made available to the scientific community to catalyze research worldwide.